Ayala Pharmaceuticals Inc
NASDAQ:AYLA
Intrinsic Value
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of AYLA.
Ayala Pharmaceuticals Inc's market capitalization is 7.2m USD.
AYLA stock price is 0.5036 USD.
AYLA.
AYLA. Open DCF Valuation
AYLA. Open Relative Valuation
AYLA.
AYLA has positive Gross Profit for the last twelve months.
AYLA's Revenue has dropped by 48% over the past 12 months.
AYLA's ROE (Return on Equity) has significantly decreased in the last 3 years from -108% to -162%, and is approaching profitability.
AYLA's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 1 716% to -2 776%.
AYLA's short-term assets (13m USD) exceed its short-term liabilties (6m USD).
AYLA has negative Operating Income for the last twelve months.
AYLA has negative Net Income for the last twelve months.
AYLA's ROE (Return on Equity) for the past 12 months is negative and is equal to -162%.
AYLA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -2 776%.
AYLA's long-term assets (14m USD) exceed its long-term liabilties (6m USD).
AYLA has negative Free Cash Flow for the last twelve months.
AYLA has negative three-year average ROE (Return on Equity): -110%. The company is not efficient at transforming stockholders' equity into net income.
AYLA has negative three-year average ROIC (Return on Invested Capital): -5 406%. The company is not efficient at using invested capital to generate operating income.
AYLA's D/E (Debt to Equity) is very low and is equal to 0.
AYLA's Altman Z-Score is very low and is equal to -21.19.
Fundamental Analysis
Ayala Pharmaceuticals Inc
Balance Sheet Decomposition
Ayala Pharmaceuticals Inc
| Current Assets | 13m |
| Cash & Short-Term Investments | 11.2m |
| Receivables | 129k |
| Other Current Assets | 1.7m |
| Non-Current Assets | 1.2m |
| PP&E | 999k |
| Other Non-Current Assets | 229k |
| Current Liabilities | 5.7m |
| Accounts Payable | 2.3m |
| Accrued Liabilities | 3.4m |
| Non-Current Liabilities | 396k |
| Other Non-Current Liabilities | 396k |
Earnings Waterfall
Ayala Pharmaceuticals Inc
|
Revenue
|
1.7m
USD
|
|
Cost of Revenue
|
-1.6m
USD
|
|
Gross Profit
|
90k
USD
|
|
Operating Expenses
|
-37.6m
USD
|
|
Operating Income
|
-37.5m
USD
|
|
Other Expenses
|
-932k
USD
|
|
Net Income
|
-38.5m
USD
|
Free Cash Flow Analysis
Ayala Pharmaceuticals Inc
What is Free Cash Flow?
AYLA Profitability Score
Profitability Due Diligence
Ayala Pharmaceuticals Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
Score
Ayala Pharmaceuticals Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
AYLA Solvency Score
Solvency Due Diligence
Ayala Pharmaceuticals Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Ayala Pharmaceuticals Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AYLA Price Targets Summary
Ayala Pharmaceuticals Inc
Ownership
AYLA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
AYLA Price
Ayala Pharmaceuticals Inc
| Average Annual Return | -22.11% |
| Standard Deviation of Annual Returns | 4.2% |
| Max Drawdown | -98% |
| Market Capitalization | 7.2m USD |
| Shares Outstanding | 15 482 809 |
| Percentage of Shares Shorted | 0.81% |
Company Profile
Ayala Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology. The company is headquartered in Wilmington, Delaware and currently employs 35 full-time employees. The company went IPO on 2020-05-08. The firm is focused on developing and commercializing small molecule therapeutics for patients suffering from rare cancers. The firm's portfolio of product candidates includes, AL101 and AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidates AL101 and AL102, are developed as potent, selective, small molecule gamma secretase inhibitors (GSIs). The firm is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of patients with Notch-activated recurrent/metastatic triple negative breast cancer (R/M TNBC). The company is developing AL101 for the treatment of T-ALL, a rare form of T-cell specific leukemia. The company is evaluating AL102 as a monotherapy in a Phase II / III pivotal study (RINGSIDE) for the treatment of desmoid tumors in adult and adolescent patients.
You don't have any saved screeners yet
